ArticleJournal of experimental & clinical cancer research : CR2026
U2 snRNP inhibition hampers pancreatic cancer cell viability by disrupting DNA repair proficiency and mitotic checkpoint integrity.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with remarkably poor prognosis. Splicing dysregulation is emerging as a hallmark and possible therapeutic target of PDAC.
methodsWe performed high-throughput RNA sequencing analyses in PANC-1 cells treated with three drugs targeting the U2 small nuclear ribonucleoprotein (U2 snRNP): Pladienolide B, Thailanstatin A and Indisulam. The efficacy of splicing inhibitors, Talazoparib, Alisertib, AZD7762 and Barisertib, alone or in combination, was assessed in PDAC cells and patient-derived organoids (PDOs) by cell viability assays. RT-PCR, western blot and cell cycle assays were performed to evaluate the expression of DNA repair and mitotic genes and the execution of mitosis. PANC-1 cells were engineered to stably co-express GFP-tagged H2b histone and RFP-tagged β-tubulin by CRISPR/Cas-9 technology and used for time-lapse confocal microscopy and immunofluorescence analyses.
resultsGenes encoding for the U2 snRNP, which recognizes the 3' splice site, are upregulated in advanced PDAC. U2 snRNP-targeting drugs impair the DNA damage response (DDR) pathway in homologous recombination-proficient PDAC cells and PDOs, thus enhancing their sensitivity to PARP inhibitors. Genes whose splicing was disrupted by all three drugs are characterized by higher expression, more exon-intron junctions, weak 5' splice sites and atypical GC content. These features are enriched in mitotic genes (e.g. AURKA, AURKB, CHEK1), whose expression is strongly deregulated by splicing perturbation. Accordingly, splicing inhibition causes severe mitotic defects, leading to the accumulation of cells with misaligned condensed chromosomes on monopolar or bipolar spindles. Notably, high expression of AURKA, AURKB and CHEK1 correlates with poor prognosis in PDAC patients, whereas combined treatments with inhibitors of these mitotic kinases strongly impair the viability of PDAC cells and PDOs.
conclusionsThese findings uncover gene features associated with sensitivity to splicing inhibitors in PDAC cells and suggest that the DDR and mitosis are biological processes highly sensitive to splicing perturbation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.